Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
This precision oncology innovator, up nearly 500% in a year, just reported significant insider selling amid ongoing drug development efforts.
Overview
On June 22, 2026, Relay Therapeutics (NASDAQ:RLAY) Chief Financial Officer Thomas Catinazzo executed an option exercise followed by the sale of 187,163 shares of Common Stock, as reported in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($16.97); post-transaction value based on the value of directly held shares after the sale using the June 22, 2026 transaction price ($16.97).
Details
* 1-year performance calculated using June 22nd, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.